CPT code 81163: BRCA testing, both genes, sequence analysis2026 Medicare lab fee · Clinical Laboratory Fee Schedule

Full-sequence analysis of BRCA1 and BRCA2 is reported for evaluation of inherited risk associated with hereditary breast and ovarian cancer.

CMS CLFS 2026 Q4Effective Oct 1, 2026Same amount nationwide134 Medicare services in 2024

Medicare pays $468.00 for 81163 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.

Medicare lab fee · CLFS 2026 Q4

National CLFS amount

$468.00

In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.

Geographic adjustment
None
Office vs facility
Same
Since 2020
Unchanged
CMS updates
Quarterly

Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.

On this page 8 sections
  1. Medicare lab fee
  2. What 81163 covers
  3. How it’s paid
  4. Amount history
  5. Similar tests
  6. Related codes
  7. Billing questions
  8. Sources

What 81163 covers

This test analyzes the full gene sequences of both BRCA1 and BRCA2, genes associated with hereditary breast and ovarian cancer. Molecular diagnostic laboratories perform the analysis for clinicians evaluating inherited cancer risk. The reported service covers sequence analysis of both genes and is distinct from analysis for large deletions or duplications. Select this code for full-sequence analysis of both genes, rather than a service that also includes deletion/duplication analysis.

Medicare pays this laboratory test under the Clinical Laboratory Fee Schedule (CLFS); it is excluded from physician fee schedule payment. The 2026 national CLFS amount is $468.00 and has remained unchanged since 2020. The amount is the same in every state and locality, with no geographic or office-versus-facility adjustment.

This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.

How Medicare pays 81163

Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.

One national amount

CMS sets a single Clinical Laboratory Fee Schedule amount for 81163. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.

No office or facility rate

Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.

Updated every quarter

CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.

Excluded from the physician fee schedule

The physician fee schedule lists 81163 with status X (excluded by statute), so the test itself is paid only from the CLFS.

81163 on the lab fee schedule since 2020

81163 · CLFS 2026 Q4 (current)

$468.00

Unchanged since Jan 1, 2020

Amount in each year’s latest CLFS release · bars start at $0

27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.

81163 compared with similar tests

81162BRCA1/2 testingFull sequence and rearrangements$1,824.88
81162 combines full-sequence analysis with deletion/duplication analysis for both genes. Choose 81163 for full-sequence analysis without that combined deletion/duplication component.
81164BRCA analysisFull duplication/deletion analysis$584.23
81164 analyzes full-gene deletions and duplications in both BRCA genes; 81163 analyzes their full sequences.
81165BRCA1 sequencingFull gene sequence$282.88
81165 is full-sequence analysis of BRCA1 alone. Use 81163 when the service analyzes both BRCA1 and BRCA2.
81166BRCA1 analysisFull duplication/deletion$301.35
81166 is full-gene deletion/duplication analysis of BRCA1 alone, rather than full-sequence analysis of both genes.

81163 billing questions

When should this code be selected instead of 81162?

Use 81163 for full-sequence analysis of BRCA1 and BRCA2. Code 81162 represents combined sequence and deletion/duplication analysis.

Does this code include deletion and duplication analysis?

No. It describes full-sequence analysis; 81164 describes full-gene deletion/duplication analysis of both BRCA genes.

Which code describes full-sequence analysis of BRCA1 alone?

Code 81165 describes full-sequence analysis of BRCA1 alone. Code 81163 covers both BRCA1 and BRCA2.

What should documentation identify?

Documentation should identify full-sequence analysis of both BRCA1 and BRCA2 as the service performed.

How does Medicare pay for this test?

Medicare pays it under the CLFS at one national amount, with the same payment across localities and care settings. It is excluded from physician fee schedule payment.

Where this amount comes from

FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.

CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027

Show the CMS file line behind this amount
CLFS row for 81163PUF_CLFS_CY2026_Q4V1.csv, line 765 (CLFS 2026 Q4)

Open CMS sourceHow we source rates

Did this answer your question about what Medicare pays for 81163?

Tell us what you were actually trying to work out. We’ll answer you directly, or build the page that does.

Fee sheets · Coming soon

Put 81163 and the rest of your codes on one sheet

Your codes at your locality, with payer contracts beside Medicare.

Join the waitlist